Loading stock data…
Pharming Group N.V (PHAR)
$13.40+0.06 (+0.45%)
After Hours$13.40+0.00 (+0.00%)· Last close Jun 29
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharming Group N.V. in the Healthcare sector is trading at $13.40 with a market capitalization of $901M. Wall Street consensus targets $34.35 (4 analysts), implying a +156.3% move over the next 12 months. The stock is currently 37% below its 52-week high of $21.34, remaining 14.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +156.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $72.45M↓ | $106.50M↑ | $97.29M↑ | $93.22M↑ | $79.09M |
| Gross Profit | $65.80M↓ | $85.40M↓ | $90.22M↑ | $84.25M↑ | $70.77M |
| Operating Income | -$5.29M↓ | $2.00M↓ | $15.75M↑ | $9.00M↑ | -$7.43M |
| Net Income | -$5.21M↓ | $5.30M↓ | $7.55M↑ | $4.69M↑ | -$14.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RU...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$901.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.58%
Volume
Today's trading volume
8,297
Recent News
Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case
Pharming Group is back in focus after analysts updated their fair value estimate from €2.11 to €2.36, giving readers fresh context for how the stock is being assessed today. Recent research frames this new €2.36 figure as a balance of optimism around growth potential and caution on execution and valuation, helping you see how bullish and bearish arguments are shaping the story. Read on to see how these moving parts fit together and how you can keep track of the evolving Pharming Group...
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
High Growth Tech Stocks in Europe with Promising Potential
The European market has shown resilience with the pan-European STOXX Europe 600 Index edging up slightly, as investors remain hopeful for geopolitical resolutions that could stabilize energy markets and boost economic confidence. In this environment, identifying high-growth tech stocks involves looking for companies with strong innovation capabilities and adaptability to current trends such as artificial intelligence and digital transformation, which can offer promising potential despite...
We Think Pharming Group's (AMS:PHARM) Profit Is Only A Baseline For What They Can Achieve
Even though Pharming Group N.V. ( AMS:PHARM ) posted strong earnings, investors appeared to be underwhelmed. We did...
Pharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their Models
Shareholders in Pharming Group N.V. ( AMS:PHARM ) had a terrible week, as shares crashed 23% to €1.10 in the week since...